Ari M. Vanderwalde
About
In The Last Decade
Ari M. Vanderwalde
116 papers receiving 3.4k citations
Hit Papers
Peers
Comparison fields: 5 of 101
- Oncology 2.6k
- Molecular Biology 847
- Immunology 845
- Pulmonary and Respiratory Medicine 832
- Genetics 785
Countries citing papers authored by Ari M. Vanderwalde
This map shows the geographic impact of Ari M. Vanderwalde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ari M. Vanderwalde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ari M. Vanderwalde more than expected).
Fields of papers citing papers by Ari M. Vanderwalde
This network shows the impact of papers produced by Ari M. Vanderwalde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ari M. Vanderwalde. The network helps show where Ari M. Vanderwalde may publish in the future.
Co-authorship network of co-authors of Ari M. Vanderwalde
This figure shows the co-authorship network connecting the top 25 collaborators of Ari M. Vanderwalde. A scholar is included among the top collaborators of Ari M. Vanderwalde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ari M. Vanderwalde. Ari M. Vanderwalde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 11 | |
| 3 | 7 | |
| 4 | 1 | |
| 5 | 1 | |
| 6 | 1 | |
| 7 | 7 | |
| 8 | 1 | |
| 9 | 6 | |
| 10 | 0 | |
| 11 | 1 | |
| 12 | 12 | |
| 13 | 16 | |
| 14 | 155 | |
| 15 | Initial results of the phase 1 portion of an ongoing phase 1/2 study of RP1 as a single agent and in combination with nivolumab in patients with solid tumors | 1 |
| 16 | Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study breakdown → | 383 |
| 17 | Microsatellite instability status determined by next‐generation sequencing and compared with | 333 |
| 18 | 2 | |
| 19 | 5 | |
| 20 | 6 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.